Chronic pretreatment with celecoxib reduces infarct size

Journal of Cardiovascular Pharmacology

Volumn 54, Issue 1, 2009, Pages 31-37

  Lada Moldovan, Laura ^a   Kaloustian, Sévan ^a   Bah, Thierno Madjou ^a   Girard, Stéphanie Anne ^a   Déry, Marc André ^a   Rousseau, Guy ^a  

^a HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

Author keywords

Aggregation; Celecoxib; Ischemia; Myocardial infarction; Reperfusion

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DRUG VEHICLE; MYELOPEROXIDASE; PROSTAGLANDIN E2; PROTEIN BAX; PROTEIN BCL 2; TUMOR NECROSIS FACTOR ALPHA; WATER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; HEART INFARCTION; HEART INFARCTION SIZE; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; NICK END LABELING; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; RAT;

ANIMALS; CYCLOOXYGENASE 2 INHIBITORS; DISEASE MODELS, ANIMAL; INFUSIONS, PARENTERAL; ISCHEMIA; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; PYRAZOLES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES;

EID: 68249138341     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181aa3905     Document Type: Article

References (42)

1. Jaksch W, Dejaco C, Schirmer M. 4 years after withdrawal of rofecoxib: where do we stand today? Rheumatol Int. 2008;28:1187-1195.
2. Chu K, Jeong SW, Jung KH, et al. Celecoxib induces functional recovery after intracerebral hemorrhage with reduction of brain edema and perihematomal cell death. J Cereb Blood Flow Metab. 2004;24:926-933. (Pubitemid 39045410)
3. Winnall WR, Muir JA, Liew S, et al. Effects of chronic celecoxib on testicular function in normal and lipopolysaccharide-treated rats. Int J Androl. 2008. [Epub ahead of print].
4. Nery FG, Monkul ES, Hatch JP, et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol. 2008;23:87-94. (Pubitemid 351359580)
5. Kaloustian S, Wann BP, Bah TM, et al. Celecoxib after the onset of reperfusion reduces apoptosis in the amygdala. Apoptosis. 2007;12: 1945-1951. (Pubitemid 47498230)
6. Myint AM, Steinbusch HW, Goeghegan L, et al. Effect of the COX-2 inhibitor celecoxib on behavioural and immune changes in an olfactory bulbectomised rat model of depression. Neuroimmunomodulation. 2007; 14:65-71. (Pubitemid 47442983)
7. Schiffmann S, Maier TJ, Wobst I, et al. The anti-proliferative potency of celecoxib is not a class effect of coxibs. Biochem Pharmacol. 2008;76: 179-187.
8. Chen JC, Chen Y, Su YH, et al. Celecoxib increased expression of 14-3-3sigma and induced apoptosis of glioma cells. Anticancer Res. 2007; 27:2547-2554. (Pubitemid 47232274)
9. Kirkova M, Alexandova A, Kesiova M, et al. Potential antioxidant activity of celecoxib and amtolmetin guacyl: in vitro studies. Auton Autacoid Pharmacol. 2007;27:13-18. (Pubitemid 44952840)
10. Ajith T, Subin JP, Jacob J, et al. Antimutagenic and anti-oxidant activities of the non-steroidal anti-inflammatory drug celecoxib. Clin Exp Pharmacol Physiol. 2005;32:888-893. (Pubitemid 43906534)
11. Shinmura K, Tang XL, Wang Y, et al. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci U S A. 2000;97:10197-10202. (Pubitemid 30680878)
12. Sato H, Bolli R, Rokosh GD, et al. The cardioprotection of the late phase of ischemic preconditioning is enhanced by postconditioning via a COX-2-mediated mechanism in conscious rats. Am J Physiol Heart Circ Physiol. 2007;293:H2557-H2564. (Pubitemid 47605904)
13. de Lorgeril M, Rousseau G, Basmadjian A, et al. Spacial and temporal profiles of neutrophil accumulation in the reperfused ischemic myocardium. Am J Cardiovasc Path. 1990;3:143-154.
14. de Lorgeril M, Basmadjian A, Lavallee M, et al. Influence of leukopenia on collateral flow, reperfusion flow, reflow ventricular fibrillation and infarct size in dogs. Am Heart J. 1989;117:523-532. (Pubitemid 19078147)
15. Libersan D, Khalil A, Dagenais P, et al. The low molecular weight heparin, enoxaparin, limits infarct size at reperfusion in the dog. Cardiovasc Res. 1998;37:656-666. (Pubitemid 28231160)
16. Mirabet M, Garcia-Dorado D, Inserte J, et al. Platelets activated by transient coronary occlusion exacerbate ischemia-reperfusion injury in rat hearts. Am J Physiol Heart Circ Physiol. 2002;283:H1134-1141. (Pubitemid 34941051)
17. Hirata Y, Umemura K, Uematsu T, et al. An experimental myocardial infarction model in the rat and its properties. Jpn J Pharmacol. 1995;67: 51-57.
18. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092-1102. (Pubitemid 40365350)
19. Zhang Z, Lai GH, Sirica AE. Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation. Hepatology. 2004;39:1028-1037. (Pubitemid 38428942)
20. Gao F, Tao L, Yan W, et al. Early anti-apoptosis treatment reduces myocardial infarct size after a prolonged reperfusion. Apoptosis. 2004;9: 553-559. (Pubitemid 39158631)
21. Zhao ZQ, Morris CD, Budde JM, et al. Inhibition of myocardial apoptosis reduces infarct size and improves regional contractile dysfunction during reperfusion. Cardiovasc Res. 2003;59:132-142.
22. Drazen JM. COX-2 inhibitors-a lesson in unexpected problems. N Engl J Med. 2005;352:1131-1132.
23. Wann BP, Bah TM, Boucher M, et al. Vulnerability for apoptosis in the limbic system after myocardial infarction in rats: a possible model for human postinfarct major depression. J Psychiatry Neurosci. 2007;32: 11-16. (Pubitemid 46276296)
24. Boucher M, Pesant S, Falcao S, et al. Post-ischemic cardioprotection by A2A adenosine receptors: dependent of phosphatidylinositol 3-kinase pathway. J Cardiovasc Pharmacol. 2004;43:416-422. (Pubitemid 38270609)
25. Saito T, Rodger IW, Hu F, et al. Inhibition of COX pathway in experimental myocardial infarction. J Mol Cell Cardiol. 2004;37:71-77. (Pubitemid 38900530)
26. Pelliccia F, Pasceri V, Granatelli A, et al. Safety and efficacy of short-term celecoxib before elective percutaneous coronary intervention for stable angina pectoris. Am J Cardiol. 2006;98:1461-1463. (Pubitemid 44779473)
27. Baxter GF. The neutrophil as a mediator of myocardial ischemia-reperfusion injury: time to move on. Basic Res Cardiol. 2002;97:268-275.
28. Mahmudi-Azer S, van Eeden SF. Neutrophil 'connectivity': key to neutrophil-mediated tissue injury? Crit Care. 2003;7:285-287.
29. Lukkarinen H, Laine J, Aho H, et al. Inhibition of COX-2 aggravates neutrophil migration and pneumocyte apoptosis in surfactant-depleted rat lungs. Pediatr Res. 2006;59:412-417. (Pubitemid 43740080)
30. Kimura T, Iwase M, Kondo G, et al. Suppressive effect of selective cyclooxygenase-2 inhibitor on cytokine release in human neutrophils. Int Immunopharmacol. 2003;3:1519-1528. (Pubitemid 37025733)
31. Ruan KH, Deng H, So SP. Engineering of a protein with cyclooxygenase and prostacyclin synthase activities that converts arachidonic acid to prostacyclin. Biochemistry. 2006;45:14003-14011. (Pubitemid 44846189)
32. Brenneis C, Maier TJ, Schmidt R, et al. Inhibition of prostaglandin E2 synthesis by SC-560 is independent of cyclooxygenase 1 inhibition. FASEB J. 2006;20:1352-1360. (Pubitemid 44943843)
33. Bezugla Y, Kolada A, Kamionka S, et al. COX-1 and COX-2 contribute differentially to the LPS-induced release of PGE2 and TxA2 in liver macrophages. Prostaglandins Other Lipid Mediat. 2006;79:93-100. (Pubitemid 43306853)
34. Abbate A, Limana F, Capogrossi MC, et al. Cyclo-oxygenase-2 (COX-2) inhibition reduces apoptosis in acute myocardial infarction. Apoptosis. 2006;11:1061-1063. (Pubitemid 43876835)
35. Wang L, Du F, Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell. 2008;133:693-703. (Pubitemid 351636305)
36. Sabbah HN, Sharov VG, Goldstein S. Cell death, tissue hypoxia and the progression of heart failure. Heart Fail Rev. 2000;5:131-138. (Pubitemid 30675945)
37. Reimer K, Lowe J, Ramussen M, et al. The wavefront phenomenon of ischemic cell death. 1-Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation. 1977;56:786-794.
38. Gladding PA, Webster MW, Farrell HB, et al. The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am J Cardiol. 2008;101: 1060-1063.
39. Graff J, Skarke C, Klinkhardt U, et al. Effects of selective COX-2 inhibition on prostanoids and platelet physiology in young healthy volunteers. J Thromb Haemost. 2007;5:2376-2385. (Pubitemid 350154346)
40. Renda G, Tacconelli S, Capone ML, et al. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clin Pharmacol Ther. 2006;80:264-274. (Pubitemid 44313900)
41. Dyszkiewicz-Korpanty A, Olteanu H, Frenkel EP, et al. Clopidogrel antiplatelet effect: an evaluation by optical aggregometry, impedance aggregometry, and the platelet function analyzer (PFA-100). Platelets. 2007;18:491-496. (Pubitemid 350034851)
42. Funakoshi-Tago M, Shimizu T, Tago K, et al. Celecoxib potently inhibits TNFalpha-induced nuclear translocation and activation of NF-kappaB. Biochem Pharmacol. 2008;76:662-671.